Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.37 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1871409 | 0.97 | — | — | |
| SCHEMBL1871416 | 0.90 | — | — | |
| SCHEMBL30787428 | 0.87 | GPR84 (0.46) | GPR84FFAR1FFAR4ACACBACACA | |
| SCHEMBL30787116 | 0.87 | GPR84 (0.46) | GPR84FFAR1FFAR4ACACBACACA | |
| SCHEMBL14660129 | 0.87 | GPR84 (0.46) | GPR84FFAR1FFAR4ACACBACACA | |
| SCHEMBL23530055 | 0.87 | GPR84 (0.46) | GPR84FFAR1FFAR4ACACBACACA | |
| SCHEMBL30787291 | 0.87 | GPR84 (0.46) | GPR84FFAR1FFAR4ACACBACACA | |
| SCHEMBL30787307 | 0.87 | GPR84 (0.46) | GPR84FFAR1FFAR4ACACBACACA | |
| SCHEMBL30787207 | 0.87 | GPR84 (0.46) | GPR84FFAR1FFAR4ACACBACACA | |
| SCHEMBL2845646 | 0.87 | GPR84 (0.46) | GPR84FFAR1FFAR4ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044070-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2011-10-25 | — | — | US | disclosed |
| US-7947831-B2 | Sulfoxides or sulfones grafted onto polymers | BASF SE Ludwigshafen (DE) | 2011-05-24 | — | — | US | disclosed |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | MSD K.K. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-7595316-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-29 | — | — | US | disclosed |
| US-20070015870-A1 | Sulfoxides or sulfones grafted onto polymers | CIBA CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-7160955-B2 | Sulfoxides or sulfones grafted onto polymers | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1642898-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
| US-20040152836-A1 | Sulfoxides or sulfones grafted onto polymers | CIBA SPECIALTY CHEMICALS CORP. | 2004-08-05 | — | — | US | disclosed |
| EP-1373196-A2 | SULFOXIDES OR SULFONES GRAFTED ONTO POLYMERS | Ciba SC Holding AG (CH) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002081432-A2 | SULFOXIDES OR SULFONES GRAFTED ONTO POLYMERS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | HRH3, HRH4, HCRTR2 | GPR84 187/4885FFAR1 132/4885FFAR4 140/4885 |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | HRH3, HRH4, HRH2 | GPR84 146/4885FFAR1 115/4885FFAR4 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.